ArticleJournal of gastrointestinal oncology2026
Paeoniflorin inhibits colorectal cancer stem cell properties via regulating LINC01711/KMT2D/KLF7 axis.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Paeoniflorin (PF) exerts anti-tumor effects in various cancers. However, the effects of PF on colorectal cancer (CRC) are still unknown. The purpose of this study was to investigate the effects of PF on CRC. Methods: Message RNA (mRNA) levels were analyzed by reverse transcription quantitative polymerase chain reaction. Protein expression was determined by Western blot. Cell migration was determined by transwell assay. Cell viability was determined using cell counting kit-8. Cell proliferation was detected using colony formation and 5-ethynyl-2'deoxyuridine assay. CRC cell stem-like properties were analyzed by sphere formation assay and flow cytometry assay. The interaction between LINC01711 and lysine methyltransferase 2D (KMT2D)/KLF transcription factor 7 (KLF7) was analyzed by RNA pull-down assay. The transcription of LINC01711 was analyzed by luciferase and chromatin immunoprecipitation assays. Results: The results showed that PF inhibited the proliferation, migration, and stem-like behaviors of CRC cells. Moreover, PF inhibited the expression of LINC01711, which formed a turnery structure with KMT2D and KLF7. This turnery structure mediated the activation of KLF7/Wnt/β-catenin signaling. However, PF blocked the interaction between LINC01711 and KMT2D/KLF7, as well as inhibited KLF7-mediated transcription and upregulation of LINC01711. Furthermore, PF inhibited the tumor growth of CRC. Conclusions: Taken together, PF inhibits CRC cell proliferation and stem-like properties via blocking LINC01711/KMT2D/KLF7 axis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.